Thomas M Schmitt

thomasschmittm
Member since Jun 8th, 2023

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents.

Radial Immunodiffusion Testing Service

Created 10 months ago

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has launched its new Single Radial Immunodiffusion Testing services for the biological industry that facilitate researchers in determining the amount or concentration of antigens in a sample.

Single radial immunodiffusion (SRID) is an agar gel precipitation test used to determine the amount or concentration of antigens in a sample. Antibodies of known specificity are uniformly distributed in an agar gel, and a sample containing the antigen of interest is placed in a well in the gel. The antigen then diffuses radially from the well to form a precipitate ring at the point of antibody-antigen equilibrium. Finally, the concentration of the antigen is determined by measuring the diameter of the precipitate ring and by extrapolation using a standard curve.

WHO guidelines require vaccine manufacturers to determine the potency of their products at the time of release and throughout the licensed shelf life. The SRID assay is the current gold standard for influenza vaccine potency. The assay is based on the diffusion of viral antigen into an agarose gel containing antibodies specific for the antigen being tested. Meanwhile, the interaction between antigen and antibody produces a precipitation zone whose size is proportional to the amount of antigen applied. Thus, the potency value of an unknown preparation can be determined by comparing the size of the precipitation zone.

Creative Diagnostics' new SRID testing services provide customers with accurate and reliable results for their samples. In addition to immunology, i.e., determining the amount or concentration of antigen in a sample, these services can be used to estimate immunoglobulin classes and IgG and IgM antibodies in serum, determine the relative purity of an antigen preparation, and perform serological studies.

The SRID testing service can provide customers with easily interpretable results, and its sensitivity and specificity depend on the quality of the antibodies used in the assay. Because SRID has been in use for decades, there is a large amount of historical data and experience. It measures the antigens considered most relevant to protection, especially those in the original conformation. It can also be used to test the potency of the final product, which is almost always polyvalent.

Creative Diagnostics' experienced scientists can provide customers with expert advice on how to optimize their assays for maximum sensitivity and specificity. The company’s state-of-the-art equipment and techniques ensure that all samples are tested to the highest standards.

For more information about Creative Diagnostics’ Single Radial Immunodiffusion Testing Service, please visit https://antiviral.creative-diagnostics.com/single-radial-immunodiffusion-srid-testing-service.html.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases

Created 10 months ago

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. These antibodies can be used in various scientific applications such as WB, ELISA, IHC, and IP to facilitate drug development research.

Coagulation Factor XIIIa (FXIIIa) is a plasma transglutaminase that catalyzes the final step of the coagulation process and plays an important role in hemostasis. FXIIIa stabilizes blood clots by cross-linking the α- and γ-chains of fibrin. It also protects the newly formed clot from plasma protein-mediated fibrinolysis by cross-linking α2-antithrombin to fibrin. Furthermore, FXIIIa is a major determinant of clot size and the amount of red blood cells in the clot.

In addition to coagulation, Factor XIII has many other functions, including maintenance of pregnancy, wound healing, immunity, adipogenesis, and angiogenesis. There is increasing evidence that FXIII targets a wide range of additional substrates and is important in venous thromboembolism, arthropathies, systemic sclerosis, and other diseases. As a result, FXIIIa has emerged as a promising target for the development of drugs and therapies for related diseases.

Creative Diagnostics now offers a set of highly specific antibodies against FXIIIa/F13A1 that can be used in various scientific applications such as WB, ELISA, IHC and IP to enhance drug discovery research. All antibodies are well validated with extensive quality control data for measured specificity. In addition, Creative Diagnostics can provide a variety of labels upon request, while ensuring consistent quality and performance with ongoing replenishment.

For example, Anti-F13A1 monoclonal antibody, clone FQ4483 (CABT-33470RH) is suitable for IHC-P, IP, and WB. The protein encoded by the gene is a member of the Ser/Thr protein kinase family, which is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex and is important for progression through the G1 phase of the cell cycle. However, the activity of this kinase is restricted to the G1-S phase and is controlled by the regulatory subunit D-type cell cycle protein and the CDK inhibitor p16 (INK4a). This kinase has been shown to be responsible for the phosphorylation of the retinoblastoma (Rb) gene product. Mutations in this gene and its related proteins, including D-type cellular proteins, p16(INK4a) and Rb, have been associated with tumorigenesis in several cancers. Moreover, several polyadenylation sites of this gene have been reported.

For more information about Creative Diagnostics’ highly specific antibodies against FXIIIα/F13A1 for vascular diseases or other products in coagulation research such as antibodies and antibody pair sets, please visit https://www.creative-diagnostics.com/fxiii-f13a1-a-promising-therapeutic-target-for-vascular-diseases.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.